The Bcl-2 inhibitor venetoclax has shown promising clinical efficacy in AML, especially in the previously untreated patients in combination with azacitidine27 and knockdown of STAB1 has been suggested to sensitize AML cell lines to venetoclax13. This evidence concerns the gene BCL2 and acute myeloid leukemia.